We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

31 hedge funds and large institutions have $6.6M invested in Matinas BioPharma in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more capital invested

Capital invested by funds: $3.66M → $6.6M (+$2.94M)

0.03% less ownership

Funds ownership: 0.18% → 0.15% (-0.03%)

21% less funds holding

Funds holding: 39 → 31 (-8)

67% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 12

70% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 10

Holders
31
Holders Change
-8
Holders Change %
-20.51%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
10
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RJFSA
Raymond James Financial Services Advisors
Florida
+$116K
2
KJHP
K.J. Harrison & Partners
Ontario, Canada
+$70.3K
3
Renaissance Technologies
Renaissance Technologies
New York
+$44.4K
4
BFM
Boothbay Fund Management
New York
+$18.3K
5
PAG
Private Advisor Group
New Jersey
+$10.7K

Top Sellers

Rank Fund Capital Flow
1
PP
Paloma Partners
Connecticut
-$138K
2
Morgan Stanley
Morgan Stanley
New York
-$137K
3
Goldman Sachs
Goldman Sachs
New York
-$87K
4
LP
LMR Partners
United Kingdom
-$86K
5
BCM
BlueCrest Capital Management
Jersey
-$72.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Commonwealth Equity Services
26
Commonwealth Equity Services
Massachusetts
$9K – – –
FC
27
Fore Capital
New York
$9K – – –
BNP Paribas Financial Markets
28
BNP Paribas Financial Markets
France
$4.41K – – –
Morgan Stanley
29
Morgan Stanley
New York
$2K -$137K -6,377 -99%
Bank of America
30
Bank of America
North Carolina
$1K -$21.1K -984 -98%
PP
31
Paloma Partners
Connecticut
– -$138K -6,350 Closed
LP
32
LMR Partners
United Kingdom
– -$86K -3,981 Closed
AGM
33
Alpine Global Management
New York
– -$55K -2,521 Closed
State Street
34
State Street
Massachusetts
– -$23K -1,023 Closed
OAM
35
Oxford Asset Management
United Kingdom
– -$14K -656 Closed
Jane Street
36
Jane Street
New York
– -$12K -552 Closed
Citadel Advisors
37
Citadel Advisors
Florida
– -$5K -225 Closed
TRCT
38
Tower Research Capital (TRC)
New York
– -$2K -111 Closed
UBS Group
39
UBS Group
Switzerland
– -$2K -88 Closed
MAM
40
Meeder Asset Management
Ohio
– -$969 -45 Closed
VFA
41
Valeo Financial Advisors
Indiana
– +$86 +4 New
1
2

MTNB Hedge Fund Activity: Q3 2018 in Review

31 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2018, worth a combined $6.6M — up 80% from $3.66M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of MTNB and 4 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 3 added.

The largest buyer was Raymond James Financial Services Advisors, adding an estimated $116K. The largest seller was Paloma Partners, exiting entirely with an estimated $138K sold.

  • 31 institutional investors held Matinas BioPharma (MTNB) as of Q3 2018, down from 39 in Q2 2018.
  • Funds reported $6.6M of Matinas BioPharma stock for Q3 2018, up 80% quarter-over-quarter.
  • 4 funds opened new Matinas BioPharma positions in Q3 2018 and 12 closed out, a net change of -8 holders.
  • The largest Matinas BioPharma buyer in Q3 2018 was Raymond James Financial Services Advisors, an estimated $116K added.
  • The largest Matinas BioPharma seller in Q3 2018 was Paloma Partners, an estimated $138K sold.

Based on aggregated 13F filings for Q3 2018.